Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 10:58:56 - browse：8314

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA cancer chief on how to get things done: ‘Don’t tell anybody'

WSS

Experimental asthma app from Apple and Anthem shows promise

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Sanders adds drug shortage policies to pandemic preparedness bill

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

What is STAT's opinion section for?

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Wikipedia

Wikipedia

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Medical school prerequisites are outdated

Trump demands the U.S. pay no more for drugs than other countries … again

AI can’t replace a physician’s gut feeling

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Medicare proposal to cover medical devices draws a mixed reaction

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AI can’t replace a physician’s gut feeling

leisure time

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

How dance can help nurses traumatized by Covid

White House drug czar issues call for 'recovery

AI can’t replace a physician’s gut feeling

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

knowledge

explore

explore

leisure time